Clinical Trial Update: Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating flortaucipir PET signal and cognitive change in early Alzheimer’s disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Flortaucipir (flortaucipir)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimer Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-08-28